Press Releases

3P Biopharmaceuticals a leading contract development and manufacturing organization specializing in process development and cGMP manufacturing for biological drugs advances its international expansion with the opening of its first commercial office in the United States located in Boston, Massachusetts. A company based in Navarre, Spain, with a 16-year history as an international CDMO, has taken a major step forward to expand its presence within the US market. This marks 3P’s first ventu

dsm-firmenich, the leading innovator in health, nutrition, and beauty, has initiated legal action for patent infringement against Zhejiang Shengda Bio-pharm Co., Ltd. – a biotin supplier – and Anhui Shengda Bio-pharm Co., Ltd., a.k.a. Anhui Shengda Bio-engineering Co., Ltd. – a biotin intermediate manufacturer. The two companies are collectively referred to as “Shengda”. dsm-firmenich asserts that Shengda’s production of a key biotin intermediate at its Anh

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit on June 20th, 2023 at 12:30 p.m. ET. The conference will be held in a virtual meeting format. A live webcast of the fireside chat will be accessible in the Investors & Media section of

OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, announced today that the first patient has been administered on June 5, in a Phase 1 clinical trial, evaluating OLX72021, an investigational RNAi therapeutic intended for the treatment of androgenic alopecia, also known as male-pattern baldness. In March, OliX received approval for the Phase 1 clinical study of OLX72021 from Bellberry Human Research Ethics Committee (Bellberry HREC) in Australia and began enrollin

Croma-Pharma®  announced today that in June the first patient will be enrolled in the clinical trial1 for the approval of its hyaluronic acid dermal filler Princess® Volume Plus Lidocaine2 in China. The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial1 is being led by Lanhzou Biotechnique Development  with the intention to confirm the efficacy and safety of Princess® Volume Plus Lidocaine in respect of mid-facial volu

Stevanato Group S.p.A. a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology and life sciences industries, unveiled today Vertiva™, the latest release of its patented On-Body Delivery System (OBDS), intended to be able to switch between basal and bolus injections and to be suitable for a wide range of subcutaneous therapies. Vertiva™’s unique design consists of a single-use pod with a pre-filled and pre-loaded 3mL

Iktos, a company specialized in Artificial Intelligence for new drug design and Curreio, Inc. a Japanese company specializing in structural analysis of biomolecules using cryo-electron microscopy, today announced a collaboration agreement in AI for new drug design. In this collaboration, Iktos’ de novo generative design technology in combination with Curreio’s state-of-the-art cryo-EM platform will be used to facilitate the rapid and cost-effective design of novel preclinical drug

GeneTex, a multinational antibody manufacturing company, is leveraging its recombinant monoclonal antibody production platform to produce best-in-class biomedical research reagents. The specificity of these new antibodies is established through meticulous in-house validation testing based on knockdown/knockout methodologies complemented by other strategies. GeneTex has employed this process to develop and thoroughly validate its new programmed death-ligand 1 (PD-L1) recombinant rabbit monoclo

OrganaBio is thrilled to announce the launch of NeoPAC™ placenta and umbilical cord tissues, its latest suite of products designed to accelerate the progress of regenerative medicine and cell therapy. By offering both Research Use Only (RUO) and clinical (cGMP) grade tissues, OrganaBio empowers researchers to tap into the potential of birth tissues, enabling the development of innovative therapies to address a wide range of medical conditions. NeoPAC™ tissues from Organa

Ecolab Inc., the world’s water, hygiene and infection prevention company, today announced a further expansion of its Purolite business with the addition of a new biologics resin manufacturing facility in Landenberg, Pennsylvania. Construction plans for the new facility are underway and will strengthen the security of supply for global pharmaceutical and biotech customers and will support the continued development and production of lifesaving clinical and commercial-scale therapeutics fo